Back to School: How biopharma can reboot drug development. Access exclusive analysis here
WASHINGTON - Genzyme Tissue Repair (GENZL) on Friday announced that it voluntarily halted its Carticel cartilage cell service pending resolution of a dispute over regulatory jurisdiction over
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury